Pilot randomized clinical trial of an SSRI vs bupropion: Effects on suicidal behavior, ideation, and mood in major depression

Neuropsychopharmacology

Volumn 37, Issue 3, 2012, Pages 697-706

  Grunebaum, Michael F ^a   Ellis, Steven P ^a   Duan, Naihua ^a   Burke, Ainsley K ^a   Oquendo, Maria A ^a   John Mann, J ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

antidepressant; clinical trial; depression; pilot; suicide

Indexed keywords

AMFEBUTAMONE; PAROXETINE;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AFFECT; AGED; BUPROPION; DEPRESSIVE DISORDER, MAJOR; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PILOT PROJECTS; SEROTONIN UPTAKE INHIBITORS; SUICIDAL IDEATION; SUICIDE; TREATMENT OUTCOME;

EID: 84855905847     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.247     Document Type: Article

References (52)

1. Baldessarini RJ (2006). Drug therapy of depression and anxiety disorders. In: Brunton LL, Lazo JS, Parker KL (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill: New York. pp 429-459.
2. Beck AT, Brown GK, Steer RA, Dahlsgaard KK, Grisham JR (1999). Suicide ideation at its worst point: a predictor of eventual suicide in psychiatric outpatients. Suicide Life Threat Behav 29:1-9. (Pubitemid 29203234)
3. Beck AT, Kovacs M, Weissman A (1979). Assessment of suicidal intention: the scale for suicide ideation. J Consult Clin Psychol 47:343-352. (Pubitemid 9157284)
4. Brower KJ, McCammon RJ, Wojnar M, Ilgen MA, Wojnar J, Valenstein M (2011). Prescription sleeping pills, insomnia, and suicidality in the National Comorbidity Survey Replication. J Clin Psychiatry 72:515-521.
5. Brown GL, Goodwin FK, Ballenger JC, Goyer PF, Major LF (1979). Aggression in human correlates with cerebrospinal fluid amine metabolites. Psychiatry Res 1:131-139. (Pubitemid 10124723)
6. Carpenter DJ, Fong R, Kraus JE, Davies JT, Moore C, Thase ME (2011). Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. J Clin Psychiatry; e-pub ahead of print 22 February 2011;e1-e12.
7. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R et al (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746-758.
8. Cleveland WS (1979). Robust locally weighted regression and smoothing scatterplots. J Amer Stat Assoc 74:829-836.
9. Corso PS, Mercy JA, Simon TR, Finkelstein EA, Miller TR (2007). Medical costs and productivity losses due to interpersonal and selfdirected violence in the United States. Am J Prev Med 32:474-482.
10. Drug Topics staff (2010a). 2009 Top 200 generic drugs by total prescriptions. Available at: http://drugtopics.modernmedicine.-com/drugtopics/ data/articlestandard/drugtopics/252010/674982/article.pdf.
11. Drug Topics staff (2010b). 2009 Top 200 branded drugs by total prescriptions. Available at: http://drugtopics.modernmedicine.com/drugtopics/ data/articlestandard//drugtopics/252010/674969/article.pdf.
12. Efron B, Tibshirani RJ (1993). An Introduction to the Bootstrap. Chapman and Hall: Boca Raton, FL.
13. Fawcett J, Scheftner WA, Fogg L, Clark DC, Young MA, Hedeker D et al (1990). Time-related predictors of suicide in major affective disorder. Am J Psychiatry 147:1189-1194. (Pubitemid 20275373)
14. First MB, Spitzer RL, Gibbon M, Williams JMG, Benjamin L (1996). Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II), (Version 2.0). Biometrics Research Department, New York State Psychiatric Institute: New York. 49 pp.
15. Fitzmaurice GM, Laird NM, Ware JH (2004). Applied Longitudinal Analysis. Wiley: Hoboken, NJ.
16. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC et al (2010). Antidepressant drug effects and depression severity: a patient-level meta-analysis. J Am Med Assoc 303:47-53.
17. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE et al (2008). Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 149:734-750.
18. Gonella G, Baignoli G, Ecari U (1990). Fluvoxamine and imipramine in the treatment of depressive patients: a doubleblind controlled study. Curr Med Res Opin 12:177-184. (Pubitemid 20256136)
19. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
20. Hammad TA, Laughren T, Racoosin J (2006). Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332-339. (Pubitemid 43345358)
21. Jacobs DG, Baldessarini RJ, Conwell Y, Fawcett JA, Horton L, Meltzer H et al (2003). Practice Guideline for the Assessment and Treatment of Patients with Suicidal Behaviors. American Psychiatric Publishing: Arlington, VA.
22. Judd FK, Moore K, Norman TR, Burrows GD, Gupta RK, Parker G (1993). A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness. Aust N Z J Psychiatry 27:49-55. (Pubitemid 23104015)
23. Kasper S, Möller H-J, Montgomery SA, Zondag E (1995). Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine. Int Clin Psychopharm 9:3-12.
24. Kessler RC, Borges G, Walters EE (1999). Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry 56:617-626. (Pubitemid 29315633)
25. Khan A, Leventhal RM, Khan SR, Brown WA (2002). Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration Database. J Clin Psychopharmacol 22:40-45. (Pubitemid 34101291)
26. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:260-268.
27. Lapierre YD (1991). Controlling acute episodes of depression. Int Clin Psychopharm 6:23-35.
28. Mahapatra SN, Hackett D (1997). A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Int J Clin Pract 51:209-213. (Pubitemid 27399648)
29. Mann JJ (2003). Neurobiology of suicidal behaviour. Nat Rev Neurosci 4:819-828. (Pubitemid 37314404)
30. Mann JJ, Apter A, Bertolote J, Beautrais A, Currier D, Haas A et al (2005). Suicide prevention strategies: a systematic review. J Am Med Assoc 294:2064-2074. (Pubitemid 41539940)
31. Mann JJ, Waternaux C, Haas GL, Malone KM (1999). Towards a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 156:181-189. (Pubitemid 29077107)
32. Marchesi C, Ceccherininelli A, Rossi A, Maggini C (1998). Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline. Pharmacopsychiatry 31:216-221. (Pubitemid 29022038)
33. Meyer RE, Salzman C, Youngstrom EA, Clayton PJ, Goodwin FK, Mann JJ et al (2010). Suicidality and risk of suicide-definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry 71:e1-e21.
34. Möller HJ, Steinmeyer EM (1994). Are serotonergic reuptake inhibitors more potent in reducing suicidality? An empirical study on paroxetine. Eur Neuropsychopharmacol 4:55-59. (Pubitemid 24087027)
35. Montgomery S, Cronholm B, Åsberg M, Montgomery DB (1978). Differential effects on suicidal ideation of mianserin, maprotiline and amitriptyline. Br J Clin Pharmac 5:77S-80S. (Pubitemid 8272678)
36. Nock MK, Hwang I, Sampson NA, Kessler RC (2010). Mental disorders, comorbidity and suicidal behavior: results from the National Comorbidity Survey Replication. Mol Psychiatry 15:868-876.
37. Oquendo MA, Galfalvy HC, Russo S, Ellis SP, Grunebaum MF, Burke AK et al (2004a). Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am J Psychiatry 161:1433-1441. (Pubitemid 38989097)
38. Oquendo MA, Halberstam B, Mann JJ (2003). Risk factors for suicidal behavior: utility and limitations of research instruments. In: First MB (ed). Standardized Evaluation in Clinical Practice. APPI Press: Washington, DC. pp 103-130.
39. Oquendo MA, Stanley B, Ellis SP, Mann JJ (2004b). Protection of human subjects in intervention research for suicidal behavior. Am J Psychiatry 161:1558-1563. (Pubitemid 39201450)
40. Owens MJ, Krulewicz S, Simon JS, Sheehan DV, Thase ME, Carpenter DJ et al (2008). Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology 33:3201-3212.
41. Pinheiro JC, Bates DM (2000). Generalized least squares. In: Mixed-Effects Models in S and S-PLUS. Springer: New York.
42. Placidi GPA, Oquendo MA, Malone KM, Brodsky B, Ellis SP, Mann JJ (2000). Anxiety in major depression: relationship to suicide attempts. Am J Psychiatry 157:1614-1618.
43. Rao CR, Wu Y (2001). On model selection. In: Lahiri P (ed). Model Selection. Institute of Mathematical Statistics: Beachwood, OH. pp 1-64.
44. Rouillon F, Phillips R, Serrurier D, Ansart E, Gérard MJ (1989). Rechutes de dépression unipolaire et efficacité de la maprotiline. L'Encéphale XV: 527-534. (Pubitemid 20017398)
45. Sacchetti E, Vita A, Guarneri L, Cornacchia M (1991). The effectiveness of fluoxetine, clomipramine, nortriptyline and desipramine in major depressives with suicidal behaviour: preliminary findings. In: Cassano GB, Akiskal HS (eds). Serotonin-Related Psychiatric Syndromes: Clinical and Therapeutic Links: Proceedings of an international meeting held under the auspices of the Italian Society of Neurosciences and sponsored by Eli Lilly Italia SpA, held in Venice on 29-31 March 1990. Royal Society of Medicine Services: London. pp 47-53.
46. Saunders K, Simon G, Bush T, Grothaus L (1998). Assessing the feasibility of using computerized pharmacy refill data to monitor antidepressant treatment on a population basis: a comparison of automated and self-report data. J Clin Psychiatry 51:883-890. (Pubitemid 28470131)
47. Schulz KF, Altman DG, Moher D (2010). CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Pharmacol Pharmacother 1:100-107.
48. Spitzer RL, Williams JBW, Gibbon M, First MB (1990). Structured Clinical Interview for DSM-III-R/DSM-IV Patient Edition (SCID-P). American Psychiatric Press: Washington, DC.
49. Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG et al (2005). Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 66:974-981. (Pubitemid 41191788)
50. Tollefson GD, Greist JH, Jefferson JW, Heiligenstein JH, Sayler ME, Tollefson SL et al (1994). Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine. J Clin Psychopharmacol 14:385-391. (Pubitemid 24378139)
51. Vinar O (1971). Scale for rating treatment emergent symptoms in psychiatry DVP. Act Nerv Super (Praha) 13:238-240.
52. Wojnar M, Ilgen MA, Wojnar J, McCammon RJ, Valenstein M, Brower KJ (2009). Sleep problems and suicidality in the National Comorbidity Survey Replication. J Psychiat Res 43:526-531.